Each combination requires its own evidence
Combining two methods may alter progression control, but the benefit and risk must be assessed for the specific combination. The effectiveness of the methods alone does not prove the safety of their simultaneous use.
The idea is to combine different stimuli that influence eye growth. This is the hypothesis tested in the study; not a guarantee of additive effect.
The most developed part of this layer includes atropine with orthokeratology. There is also increasing data regarding RLRL with spectacle designs and orthokeratology.
Go to full timelineA Spanish RCT showed greater axis control when RLRL was added to orthokeratology than with orthokeratology alone.
Small, single-center and unblinded trial. This is a combination treatment study, not a European monotherapy RCT RLRL .
Publication, Authors and RestrictionsThe review is not a substitute for checking a specific intervention. The publication date and query end date may vary.
A meta-analysis of RCTs showed additional inhibition of axis extension for low atropine with orthokeratology compared to orthokeratology alone.
Differences in observation times and protocols; collective benefit does not imply indication for every combination.
Publication, Authors and RestrictionsThe conclusions depend on the pair of interventions and the time of the study. We don't assume that a short-term advantage means the same difference in adulthood.
Monitoring must take into account both components, tolerance and possible contraindications of the device. The safety of concurrent RLRL and atropine cannot be derived from a study comparing two separate arms.
DIMS + RLRL in the referenced work is a retrospective analysis; RLRL + orthokeratology in Spain is a small RCT. None of this work establishes the best pattern for every child.
The combination is considered individually, including: with an insufficient response to the current proceedings. The decision must be based on the evidence for this combination and documentation of both interventions.
This is a framework for a conversation with a specialist, not an individual treatment plan.
In a retrospective analysis, DIMS + RLRL was associated with greater axis control than either method alone.
Lack of randomization, unequal groups and no monofocal lens group. It does not establish a standard or ranking of all methods.
Publication, Authors and RestrictionsThe study compares RLRL with atropine 0,01% in a crossover design.
It does not examine the simultaneous use of both methods. The choroidal parameters publication from DOI 10.1007 /s40123- 025-01169-0 describes the initial phase of the same study; We don't double the attempt.
Publication, Authors and RestrictionsCochrane 2025 indicates that pharmacological and optical interventions may reduce progression, but the certainty of results and long-term data are mixed.
Last query 19.02.2024 . Does not include all tests with 2025–2026 ; poorly connected networks do not justify simple product ranking.
Publication, Authors and RestrictionsIMI 2025 organizes optical, pharmacological, environmental and lighting strategies and the state of research on their effects.
Mature technologies and emerging methods have a different evidence base. The inspection is not an individual clinical eligibility assessment of the child.
Publication, Authors and RestrictionsESO and IMI present a framework for the selection of management, prevention and monitoring of myopia progression.
The guidelines require reference to current knowledge, local availability and the specific patient.
Publication, Authors and Restrictions